UK NICE recommends use of Opdivo + Yervoy (nivolumab + ipilimumab) for advanced (unresectable or metastatic) melanoma - BMS
UK's NICE has recommended that the combination of Opdivo + Yervoy (nivolumab + ipilimumab), from BMS, for the treatment of advanced (unresectable or metastatic) melanoma is approved for use by the NHS in the UK. The move comes just weeks after the European Commission's May approval Opdivo and Yervoy - the first time the regulator had licensed two immuno-oncology drugs.
NICE ruled that the cost per QALY for Opdivo + Yervoy was likely less than �30,000 for a patient population of BRAF+ and - advanced melanoma. The decision has been given just weeks after the European Commission's approval of Opdivo + Yervoy which took place in May 2016.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins